Ministry of Health and Family Welfare

Indigenous Manufacturing of Medical Equipments

Posted On: 23 SEP 2020 6:57PM by PIB Delhi

India is 86% import-dependent on Medical Devices/equipments. The various segments of devices/equipments imported are Electronics Equipment, Surgical Instruments, Conusumable& Disposables, IVD Reagent and Implants.

Various schemes/initiatives have been formulated to promote domestic manufacturing of medical devices/equipments and attract large investment in the sector:

  1. National Biopharma Mission.
  2. DBT-AMTZ COMManD [Covid-19 Medtech Manufacturing Development] Consortia launched by Department of Biotechnology (DBT) with Andhra Pradesh Med-tech Zone (AMTZ).
  • III. National Biomedical Resource Indigenisation Consortium constituted as a Public Private Partnership.
  • IV. BioNEST scheme of Biotechnology Industry Research Assistance Council (BIRAC).
  1. Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices.
  • VI. Scheme for "Promotion of Medical Devices Parks".

Under the National Biopharma Mission, a total investment of Rs.148.79 crores has been committed for establishment of infrastructure and facilities for manufacturing and testing of medical devices. A total of 9 such facilities have been funded. The state-wise distribution is as below:

States

Amount (Rs. in crores)

Andhra Pradesh

83.20

Karnataka

12.70

Maharashtra

11.09

Telangana

22.71

Uttar Pradesh

19.09

 

Indian pharma industry is reliant on bulk drug imports amounting to around USD 3.5 bn (approximately Rs.25752 crore) a year based on the data of the last two years.

The imports are mainly in Key Staring Materials (KSMs), drug intermediates and some of the Active Pharmaceutical Ingredients (APIs).

The Government has approved the following schemes to promote domestic manufacturing in the sector:

  1. The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore during a period of five years.
  2. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs. 6,940 crore during a period of eight years.

The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey stated this in a written reply in the Lok Sabha here today.                                                                                                                                      

****

MV/SJ

HFW /23September2020



(Release ID: 1658285) Visitor Counter : 431